Bryan Garnier - HUMANIGEN (HGEN.O) HUMANIGEN: Looking ahead of the major inflection point in 2021 | BUY | USD30 (+82%)

Report

Bryan Garnier

Olga Smolentseva

HUMANIGEN: Looking ahead of the major inflection point in 2021 | BUY | USD30 (+82%)

HUMANIGEN - BUY | USD30 (+82%)
Looking ahead of the major inflection point in 2021

Cash position strengthened by additional debt financing
Looking ahead of the major inflection point
Potential catalysts beyond COVID-19, could provide additional upside

11/03/2021 4 EN

Underlying

HUMANIGEN

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Olga Smolentseva

Other Reports on these Companies

Bryan Garnier

Coverage dropped

October 11, 2022 October 11, 2022 1 EN

Bryan Garnier

HUMANIGEN: ACTIV-5/BET-B did not achieve statistical significance, pipeline reprioritization needed | UNDER REVIEW | Under Review

July 14, 2022 July 14, 2022 1 EN

Bryan Garnier

HUMANIGEN (NEUTRAL, TP USD17) | Lancet publication and regulatory update for lenzilumab

December 3, 2021 December 3, 2021 3 EN

Onward: Model Update

We update our financial model after Onward medical released FY 2023 results last week The rating remains unchanged with a Buy recommendation and EUR 20 PT.

22h / 5m 22h / 5m 1 EN

Cedric Rossi

Cedric Rossi

Hugo Boss: Weak China and month of April spoilt the mood

In our view, the sharp negative market reaction was triggered by subdued trends in China and April trends which were slightly below the Q1 top-line performance (+6% FX-n), on top of another tough comparison base (Q2 2023: +20% FX-n). Whilst FY24 outlook was reiterated, management's relatively cauti

22h / 53m 22h / 53m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis reports Q1, on track with US trial

Egetis reported Q1 2024 results with an operating loss of SEK (68.6m) and a cash position of SEK 251.7m. In the pipeline, the most important update has been to the status of the critical US phase 3 trial, where the company reported that 13/16 patients have been recruited, whereof 6 patients have co

22h / 53m 22h / 53m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

HUMANIGEN: Looking ahead of the major inflection point in 2021 | BUY | USD30 (+82%)

Coverage dropped

HUMANIGEN: ACTIV-5/BET-B did not achieve statistical significance, pipeline reprioritization needed | UNDER REVIEW | Under Review

HUMANIGEN (NEUTRAL, TP USD17) | Lancet publication and regulatory update for lenzilumab

Onward: Model Update

Hugo Boss: Weak China and month of April spoilt the mood

Egetis reports Q1, on track with US trial

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe